Literature DB >> 29970391

Allogeneic transplantation using TLI-ATG conditioning for Hodgkin lymphoma after failure of autologous transplantation.

Michael A Spinner1, Ranjana H Advani1, Richard T Hoppe2, Robert Lowsky3, Lori S Muffly3.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29970391      PMCID： PMC6039652          DOI： 10.1182/bloodadvances.2018021071

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  10 in total

1.  Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma.

Authors:  Robert Chen; Ajay K Gopal; Scott E Smith; Stephen M Ansell; Joseph D Rosenblatt; Kerry J Savage; Joseph M Connors; Andreas Engert; Emily K Larsen; Dirk Huebner; Abraham Fong; Anas Younes
Journal:  Blood       Date:  2016-07-18       Impact factor: 22.113

2.  Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma.

Authors:  Reid W Merryman; Haesook T Kim; Pier Luigi Zinzani; Carmelo Carlo-Stella; Stephen M Ansell; Miguel-Angel Perales; Abraham Avigdor; Ahmad S Halwani; Roch Houot; Tony Marchand; Nathalie Dhedin; Willy Lescaut; Anne Thiebaut-Bertrand; Sylvie François; Aspasia Stamatoullas-Bastard; Pierre-Simon Rohrlich; Hélène Labussière Wallet; Luca Castagna; Armando Santoro; Veronika Bachanova; Scott C Bresler; Amitabh Srivastava; Harim Kim; Emily Pesek; Marie Chammas; Carol Reynolds; Vincent T Ho; Joseph H Antin; Jerome Ritz; Robert J Soiffer; Philippe Armand
Journal:  Blood       Date:  2017-01-10       Impact factor: 22.113

3.  Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.

Authors:  Robert Chen; Pier Luigi Zinzani; Michelle A Fanale; Philippe Armand; Nathalie A Johnson; Pauline Brice; John Radford; Vincent Ribrag; Daniel Molin; Theodoros P Vassilakopoulos; Akihiro Tomita; Bastian von Tresckow; Margaret A Shipp; Yinghua Zhang; Alejandro D Ricart; Arun Balakumaran; Craig H Moskowitz
Journal:  J Clin Oncol       Date:  2017-04-25       Impact factor: 44.544

4.  Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.

Authors:  Joseph M Connors; Wojciech Jurczak; David J Straus; Stephen M Ansell; Won S Kim; Andrea Gallamini; Anas Younes; Sergey Alekseev; Árpád Illés; Marco Picardi; Ewa Lech-Maranda; Yasuhiro Oki; Tatyana Feldman; Piotr Smolewski; Kerry J Savage; Nancy L Bartlett; Jan Walewski; Robert Chen; Radhakrishnan Ramchandren; Pier L Zinzani; David Cunningham; Andras Rosta; Neil C Josephson; Eric Song; Jessica Sachs; Rachael Liu; Hina A Jolin; Dirk Huebner; John Radford
Journal:  N Engl J Med       Date:  2017-12-10       Impact factor: 91.245

Review 5.  Should all patients with Hodgkin lymphoma who relapse after autologous SCT be considered for allogeneic SCT?

Authors:  Karl S Peggs
Journal:  Blood Adv       Date:  2018-04-10

Review 6.  Should all patients with HL who relapse after ASCT be considered for allogeneic SCT? A consult, yes; a transplant, not necessarily.

Authors:  Craig H Moskowitz
Journal:  Blood Adv       Date:  2018-04-10

7.  HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity.

Authors:  Michael A Spinner; Marcelo Fernández-Viña; Lisa E Creary; Olivia Quinn; Linda Elder; Sally Arai; Laura J Johnston; Everett H Meyer; David B Miklos; Lori S Muffly; Robert S Negrin; Judith A Shizuru; Wen-Kai Weng; Ginna G Laport; Samuel Strober; Robert Lowsky; Andrew R Rezvani
Journal:  Blood Adv       Date:  2017-07-25

8.  Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Craig H Moskowitz; Auayporn Nademanee; Tamas Masszi; Edward Agura; Jerzy Holowiecki; Muneer H Abidi; Andy I Chen; Patrick Stiff; Alessandro M Gianni; Angelo Carella; Dzhelil Osmanov; Veronika Bachanova; John Sweetenham; Anna Sureda; Dirk Huebner; Eric L Sievers; Andy Chi; Emily K Larsen; Naomi N Hunder; Jan Walewski
Journal:  Lancet       Date:  2015-03-19       Impact factor: 79.321

9.  Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.

Authors:  Anas Younes; Armando Santoro; Margaret Shipp; Pier Luigi Zinzani; John M Timmerman; Stephen Ansell; Philippe Armand; Michelle Fanale; Voravit Ratanatharathorn; John Kuruvilla; Jonathon B Cohen; Graham Collins; Kerry J Savage; Marek Trneny; Kazunobu Kato; Benedetto Farsaci; Susan M Parker; Scott Rodig; Margaretha G M Roemer; Azra H Ligon; Andreas Engert
Journal:  Lancet Oncol       Date:  2016-07-20       Impact factor: 41.316

10.  Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.

Authors:  Philippe Armand; Andreas Engert; Anas Younes; Michelle Fanale; Armando Santoro; Pier Luigi Zinzani; John M Timmerman; Graham P Collins; Radhakrishnan Ramchandren; Jonathon B Cohen; Jan Paul De Boer; John Kuruvilla; Kerry J Savage; Marek Trneny; Margaret A Shipp; Kazunobu Kato; Anne Sumbul; Benedetto Farsaci; Stephen M Ansell
Journal:  J Clin Oncol       Date:  2018-03-27       Impact factor: 44.544
  10 in total
  1 in total

1.  Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort.

Authors:  Michael A Spinner; Vanessa E Kennedy; John S Tamaresis; Philip W Lavori; Sally Arai; Laura J Johnston; Everett H Meyer; David B Miklos; Lori S Muffly; Robert S Negrin; Andrew R Rezvani; Judith A Shizuru; Wen-Kai Weng; Richard T Hoppe; Samuel Strober; Robert Lowsky
Journal:  Blood Adv       Date:  2019-08-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.